Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28991115 | 0.84 | BRD4 (0.39) | GLSDGAT1BRD4 | |
| SCHEMBL30076388 | 0.84 | GLS (0.34) | GLSDGAT1BRD4NPC1 | |
| SCHEMBL28991142 | 0.84 | GLS (0.34) | GLSDGAT1BRD4NPC1 | |
| SCHEMBL27228422 | 0.84 | BRD4 (0.33) | GLSBRD4 | |
| SCHEMBL3516228 | 0.81 | GLS (0.57) | GLSNPC1 | |
| SCHEMBL24153548 | 0.81 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL31104178 | 0.80 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL12175756 | 0.79 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL2144638 | 0.79 | NPC1 (0.46) | GLSDGAT1BRD4NPC1 | |
| SCHEMBL30286420 | 0.79 | DGAT1 (0.35) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-2563358-A1 | INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) | Merck Sharp & Dohme Corp. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PALIWAL SUNIL (US) | 2013-02-28 | — | — | US | disclosed |
| WO-2011137219-A1 | INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) | SCHERING CORPORATION (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053382-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PDK1, PDPK1, PDK3 | GLS 1020/4885DGAT1 1076/4885AAK1 351/4885 |
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | GLS 781/4885DGAT1 2579/4885AAK1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.